CAMBRIDGE, Mass.--(BUSINESS WIRE)--Liberate Bio, Inc., a company delivering genetic medicines that transcend liver-based limitations, announced an oral presentation demonstrating the success of their RAPTOR™ screening platform and its first generation of extrahepatic lipid nanoparticles at the Oligonucleotide and Peptide Therapeutics 2024 (TIDES) being held May 14-17, 2024, in Boston, Massachusetts..

马萨诸塞州剑桥市。-（商业新闻短讯）--解放生物公司（Release Bio，Inc.）是一家提供超越肝脏限制的基因药物的公司，它宣布了一项口头演示，展示了他们的RAPTOR™筛选平台及其第一代肝外脂质纳米颗粒在2024年5月14日至17日于马萨诸塞州波士顿举行的寡核苷酸和肽治疗2024（TIDS）上的成功。。

“We are excited to demonstrate both the establishment of our Rapid Particle Optimizer (RAPTOR™) platform and the first results from our high-throughput screening in the platform at TIDES,” said Walter R. Strapps, Ph.D., Chief Scientific Officer of Liberate. “The presentation demonstrates our ability to rapidly screen a diverse lipid library, designed rationally and by generative artificial intelligence, directly in non-human primates to the genetic medicines community.

Liberate首席科学官Walter R.Strapps博士说：“我们很高兴能够展示我们的快速粒子优化器（RAPTOR™）平台的建立，以及我们在潮汐平台上进行高通量筛选的首批结果。”。“该演讲证明了我们能够直接在非人类灵长类动物中向遗传药物界快速筛选合理设计并通过生成人工智能设计的多种脂质文库。

We have dramatically reduced the time, cost, and development risk of creating extrahepatic delivery vehicles that will liberate patients from genetic diseases.”.

我们已经大大减少了创建肝外运载工具的时间，成本和发展风险，这将使患者从遗传疾病中解放出来。”。

Key Highlights from the Presentation:

演讲的主要亮点：

Liberate Bio has built a robust nanoparticle screening platform for evaluating and identifying extrahepatic delivery vehicles directly in non-human primates (NHPs) – RAPTOR™. RAPTOR™ combines the power of high throughput screening with artificial intelligence to efficiently explore vast design spaces covering lipid chemistry, formulation characteristics, and targeting approaches.

Release Bio建立了一个强大的纳米粒子筛选平台，用于直接评估和鉴定非人灵长类动物（NHPs）-猛禽（RAPTOR™）中的肝外递送载体。RAPTOR™将高通量筛选与人工智能相结合，有效探索涵盖脂质化学，配方特征和靶向方法的广阔设计空间。

RAPTOR™ has identified lead candidates with enrichment in bone marrow, spleen, and cardiac tissue from a diverse library of more than 150 LNPs across multiple structural and chemically distinct classes of ionizable lipids..

RAPTOR™已从多种结构和化学上不同类别的可电离脂质中，从150多个LNP的多样文库中鉴定出富含骨髓，脾脏和心脏组织的主要候选物。。

TIDES Presentation Details:

潮汐演示详细信息：

TITLE: “RAPTOR: A High Throughput Platform for Screening LNPs in Primates”

标题：“猛禽：用于筛选灵长类动物LNP的高通量平台”

SESSION TITLE: Delivery of Macromolecules

会议标题：大分子的传递

PRESENTATION TYPE: Oral

演示类型：口头

PRESENTER: Walter R. Strapps, PhD, Chief Scientific Officer, Liberate Bio

主持人：Walter R.Strapps博士，解放生物首席科学官

DATE AND TIME: Thursday, May 16, 2024, from 4:45 p.m. – 5:15 p.m. ET

日期和时间：2024年5月16日星期四，美国东部时间下午4:45–5:15

About Liberate Bio

关于解放生物

Our vision at Liberate Bio is to achieve the extraordinary—delivering genetic medicines that transcend liver-based limitations, liberating patients from disease. Today’s genetic medicines are limited by the availability of safe, effective delivery vehicles that direct nucleic acid therapeutics to any organ other than the liver.

我们在解放生物的愿景是实现超越肝脏限制的非凡遗传药物，将患者从疾病中解放出来。今天的基因药物受到安全有效的运载工具的限制，这些运载工具将核酸疗法导向肝脏以外的任何器官。

To realize the full potential of genetic medicines, we use our proprietary screening platform to rapidly evaluate rational and artificial intelligence-designed nanoparticles, reducing the cycle time for identifying novel vehicles from years to months. We have built the team and a suite of tools that allows us to rapidly move RNA therapeutics to the clinic by significantly increasing the translatability of the preclinical work..

为了实现遗传药物的全部潜力，我们使用专有的筛选平台快速评估合理和人工智能设计的纳米颗粒，将识别新型载体的周期从数年缩短到数月。我们已经建立了团队和一套工具，通过显着提高临床前工作的可翻译性，我们可以快速将RNA疗法转移到临床。。

For more information about the company’s technologies, team, and mission, visit www.liberatebio.com.

有关公司技术、团队和使命的更多信息，请访问www.releasebio.com。